Wall Street Rallies Behind Lexeo Therapeutics (LXEO)'s Gene Therapy Pipeline [Yahoo! Finance]
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: Yahoo! Finance
a consensus buy from all eleven analysts covering the stock. While the target price ranges from $12 to $30, the median price target of $19 translates to an upside potential of 79.92%. On December 18, Raymond James initiated coverage on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with a ‘Strong Buy' rating and a price target of $25, citing solid results from two Phase 1/2 clinical trials and encouraging feedback from the FDA. With that said, the company's lead candidate, LX2006, an AAV gene therapy for cardiomyopathy associated with Friedreich's Ataxia, is “well-positioned for success” in its pivotal trial, the analyst asserted. Photo by National Cancer Institute on Unsplash Raymond James expects the stock to gain momentum in 2026 following a finalized pivotal protocol with the FDA and initial proof of concept data on LX2020, an unmodeled gene therapy asset. The firm anticipates LX2006 revenue of $14.1 million in FY27, going as high as $805.3 million in FY32. Earlier on December 10,
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Raymond James Sees an Attractive Setup in These 2 ‘Strong Buy' Stocks [Yahoo! Finance]Yahoo! Finance
- Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Lexeo Therapeutics (NASDAQ:LXEO) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.MarketBeat
- Lexeo Therapeutics (NASDAQ:LXEO) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating on the stock.MarketBeat
LXEO
Earnings
- 8/14/25 - Beat
LXEO
Sec Filings
- 12/8/25 - Form SCHEDULE
- 11/28/25 - Form EFFECT
- 11/26/25 - Form 424B3
- LXEO's page on the SEC website